<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076957</url>
  </required_header>
  <id_info>
    <org_study_id>127CRC16009</org_study_id>
    <nct_id>NCT03076957</nct_id>
  </id_info>
  <brief_title>A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj.</brief_title>
  <official_title>A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj. in Patients With Previously Treated Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label, dose-escalation phase I trial is to evaluate the safety,
      tolerability and pharmacokinetic profiles and to assess the efficacy of CKD-516 Tablet in
      Combination with Irinotecan inj. in Patients with Previously Treated Advanced Colorectal
      Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CKD-516 tab. in combination with Irinotecan inj.(1cycle=14days)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose(MTD)</measure>
    <time_frame>Up to 14 days(for 1st cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics(Cmax)</measure>
    <time_frame>1st Cycle Day1: up to 24hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with toxicity as assessed by CTCAE v4.03 through study completion, an average of 1 year</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treat Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-516(investigational Drug) Irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-516 Tablet</intervention_name>
    <description>CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.</description>
    <arm_group_label>Treat Regimen</arm_group_label>
    <other_name>CKD-516</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged 19 years or older

          2. Patients who failed existing anti-cancer therapies

          3. ECOG performance status ≤ 1

          4. Life expectancy of ≥ 12 weeks

          5. Adequate hematological, hepatic and renal functions:

          6. Patients who give written informed consent voluntarily

        Exclusion Criteria:

          1. Prior systemic chemo-, radiochemo-, radio-, immuno-, hormonal and/or biological
             therapy within 2 weeks before study participation (in case of nitrosoureas and/or
             mitomycin, within 6 weeks before study participation)

          2. Patients who received major surgery within 4 weeks before study participation (in case
             of VATS and/or ONC surgery, within 2 weeks before study participation)

          3. Symptomatic CNS metastases (patients with radiologically and neurologically stable
             metastases and being off corticosteroids for at least 4 weeks are able to participate
             in this trial.)

          4. NYHA class III or IV heart failure, uncontrolled hypertension (SBP/DBP &gt; 140/90 mm
             Hg), other clinically significant cardiovascular abnormalities at investigator's
             discretion (e.g., LVEF &lt; 50%, clinically significant cardiac wall abnormalities or
             cardiac muscle damages)

          5. Acute coronary syndrome (unstable angina or myocardial infarction) within 6 months

          6. Uncontrolled arrhythmia

          7. Significant cerebrovascular diseases including stroke within 6 months

          8. Significant vascular diseases including aortic aneurysm requiring treatment or
             peripheral arterial diseases

          9. Patients with known active hepatitis, HIV infection, or other uncontrolled infectious
             disease

         10. Patients who cannot receive IP by mouth and have a history of clinically significant
             gastrointestinal disorders which can impede administration, transit or absorption of
             the IP

         11. A history of severe drug hypersensitivity or hypersensitivity to analogs of the IP

         12. Pregnancy or breast-feeding

         13. Women of childbearing potential (WOCBP) or men who are unwilling to use adequate
             contraception or be abstinent during the trial and for at least 3 months after the end
             of treatment

         14. Patients who received other investigational products or used other investigational
             devices within 3 weeks before participation

         15. Patients who cannot participate in this trial by investigator's discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae won KIM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae won KIM, MD</last_name>
    <email>twkimmd@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae won KIM, MD</last_name>
      <email>twkimmd@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

